Insider Selling: Electromed, Inc. (NYSE:ELMD) Director Sells 38,954 Shares of Stock

Electromed, Inc. (NYSE:ELMD) Director Kathleen Skarvan sold 38,954 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $29.28, for a total transaction of $1,140,573.12. Following the completion of the transaction, the director now directly owns 32,622 shares of the company’s stock, valued at $955,172.16. This represents a 54.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kathleen Skarvan also recently made the following trade(s):

• On Friday, February 14th, Kathleen Skarvan sold 8,640 shares of Electromed stock. The shares were sold at an average price of $32.25, for a total transaction of $278,640.00.

Electromed Trading Down 2.5 %

Shares of ELMD opened at $28.63 on Friday. Electromed, Inc. has a twelve month low of $13.74 and a twelve month high of $35.56. The firm’s fifty day simple moving average is $31.40 and its 200-day simple moving average is $25.17. The firm has a market capitalization of $245.07 million, a price-to-earnings ratio of 38.17 and a beta of 0.33.

Institutional Investors Weigh In On Electromed

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new stake in Electromed during the 4th quarter worth $37,000. IFP Advisors Inc acquired a new stake in Electromed during the 4th quarter worth $59,000. Quantbot Technologies LP acquired a new stake in Electromed during the 4th quarter worth $99,000. Bank of America Corp DE raised its stake in Electromed by 179.2% during the 4th quarter. Bank of America Corp DE now owns 4,004 shares of the company’s stock worth $118,000 after acquiring an additional 2,570 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Electromed during the 4th quarter worth $119,000. 40.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELMD has been the topic of a number of analyst reports. B. Riley initiated coverage on shares of Electromed in a report on Thursday. They issued a “buy” rating and a $38.00 price objective on the stock. StockNews.com lowered shares of Electromed from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.